Stress-induced relapse to cocaine seeking: roles for the CRF2 receptor and CRF-binding protein in the ventral tegmental area of the rat
- First Online:
- 604 Downloads
Footshock reinstates cocaine seeking in cocaine-experienced rats by inducing corticotropin-releasing factor (CRF) and glutamate release in the ventral tegmental area (VTA) and thus activating VTA dopaminergic neurons. Footshock-induced VTA glutamate release, dopamine activation and reinstatements are blocked by VTA administration of a α-helical CRF, a nonselective CRF receptor antagonist. The effects of selective CRF antagonists have not yet been reported.
The present studies were designed to explore the roles of VTA CRF receptor subtypes and CRF-BP in these effects induced by footshock.
Rats were first trained to lever-press for intravenous cocaine (1 mg/infusion/0.13 ml, FR-1 schedule), and then tested under extinction conditions until response rates returned to the pretraining baseline. Reinstatements, VTA glutamate and dopamine levels [microdialysis with high performance liquid chromatography (HPLC)] were then assessed, under various pharmacological conditions, after mild inescapable footshock.
Footshock-induced reinstatement of cocaine seeking and release of VTA glutamate and dopamine were blocked by selective blockade of VTA CRF2 receptors (CRF2Rs) but not CRF1Rs. VTA perfusion of CRF or CRF2R agonists that have strong affinity for CRF-BP mimicked the effects induced by footshock while CRFR agonists that do not bind CRF-BP were ineffective. CRF6–33, which competes for the CRF binding site on CRF-BP, attenuated the effects of CRF or urocortin I on VTA glutamate and dopamine release and on reinstatement of cocaine seeking.
The present studies revealed a role of VTA CRF-BP and suggest an involvement of CRF2R in the effectiveness of stress in triggering glutamate and dopamine release and cocaine seeking in drug-experienced animals.
KeywordsStress Addiction Cocaine Corticotropin-releasing factor Binding protein Reinstatement
- Chen C, Wilcoxen KM, Huang CQ, Xie Y-F, McCarthy JR, Webb TR, Zhu Y-F, Saunders J, Liu X-J, Chen T-K, Bozigian H, Grigoriadis DE (2004) Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor agonists. J Med Chem 47:4787–4798PubMedCrossRefGoogle Scholar
- Heinrichs SC, Lapsansky J, Behan DP, Chan RK, Sawchenko PE, Lorang M, Ling N, Vale WW, De Souza EB (1996) Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal. Proc Natl Acad Sci U S A 93:15475–15480PubMedCrossRefGoogle Scholar
- Linton EA, Wolfe CDA, Behan DP, Lowry PJ (1988) A specific carrier substance for human corticotropiin-releasing factor in late gestational maternal plasma which could mask the ACTH-releasing activity. Clin Endocrinol 28:315–324Google Scholar
- Morales MF, Roach E, Diaz-Ruiz O (2005) CRF binding protein in the rat VTA. Soc Neurosci Abstr No. 639.3Google Scholar
- Pollandt S, Liu J, Orozco-Cabal L, Grigoriadis DE, Vale WW, Gallagher JP, Shinnick-Gallagher P (2006) Cocaine withdrawal enhances long-term potentiation induced by corticotropin-releasing factor at central amygdala glutamatergic synapses via CRF1, NMDA receptors and PKA. Eur J Neurosci 24:1733–1743PubMedCrossRefGoogle Scholar
- Tagliaferro AP, Morales MF (2005) CRF synapses in the rat ventral tegmental area. Soc Neurosci Abstr No. 872.10Google Scholar